Claims for Patent: 10,239,883

Summary for Patent: 10,239,883

Title:	4-imidazopyridazin-1-yl-benzamides as BTK inhibitors
Abstract:	The present invention relates to 6-5 membered fused pyridine ring compounds according to Formula (I) ##STR00001## or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to Formula (I) in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.
Inventor(s):	Barf; Tjeerd A. (Ravenstein, NL), Jans; Christiaan Gerardus Johannes Maria (Cuijk, NL), de Man; Adrianus Petrus Antonius (Hurwenen, NL), Oubrie; Arthur A. (Wijchen, NL), Raaijmakers; Hans C. A. (Eindhoven, NL), Rewinkel; Johannes Bernardus Maria (Berghem, NL), Sterrenburg; Jan Gerard (Renkum, NL), Wijkmans; Jacobus C. H. M. (Oss, NL)
Assignee:	Merck Sharp & Dohme B.V. (Haarlem, NL)
Application Number:	15/668,385
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,239,883
Patent Claims:	1. A method of treating chronic lymphocytic leukemia in a human subject, the method comprising administering to the human subject a compound that is (S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1- -yl)-N-(pyridin-2-yl)benzamide, having the structure: ##STR00187## or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein the compound is present in a pharmaceutical composition. 3. The method of claim 2, wherein the pharmaceutical composition comprises one or more pharmaceutically acceptable auxiliaries. 4. The method of claim 2, wherein the pharmaceutical composition is administered to the human subject by oral administration. 5. The method of claim 3, wherein the pharmaceutical composition is administered to the human subject by oral administration. 6. The method of claim 4, wherein the pharmaceutical composition is a tablet. 7. The method of claim 5, wherein the pharmaceutical composition is a tablet. 8. The method of claim 4, wherein the pharmaceutical composition is a capsule. 9. The method of claim 5, wherein the pharmaceutical composition is a capsule. 10. The method of claim 4, wherein the pharmaceutical composition is a suspension. 11. The method of claim 5, wherein the pharmaceutical composition is a suspension. 12. The method of claim 1, wherein the compound is administered to the human subject in an amount of 0.0001-25 mg per kg body weight. 13. The method of claim 1, wherein (S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl- )-N-(pyridin-2-yl)benzamide is administered to the human subject. 14. The method of claim 1, wherein a pharmaceutically acceptable salt of (S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl- )-N-(pyridin-2-yl)benzamide is administered to the human subject.